PPARG and type 2 diabetes mellitus: BCP has been shown to activate PPARγ, the main target of clinically used insulin sensitizers, thiazolidinedione drugs which are pharmacologically known as PPARγ agonists and used in IR and T2DM as insulin sensitizers [58].